Zhang X, et al. - In patients with peripheral T-cell lymphomas (PTCLs), the links between plasma soluble programmed death-ligand 1 (sPD-L1) levels and clinical response were assessed in this study with 37 PTCLs patients and 20 healthy volunteers. Before systemic therapy, researchers collected peripheral blood from patients. They used enzyme-linked immunosorbent assay to measure sPD-L1 and IFN-γ levels in plasma samples. They performed immunohistochemistry to detect PD-L1 expression in tissues. A higher sPD-L1 level was detected in PTCLs patients vs healthy volunteers. Findings revealed a correlation of high sPD-L1 level with worse clinical response, indicating that sPD-L1 level served as a plasma biomarker to predict the prognosis for PTCLs patients.